Celgene Gets Final OK For $239M Deal, Atty Fees
Investors in biopharmaceutical company Celgene Corp. have gotten a final nod for their $239 million deal to end proposed class claims that the company overstated commercial prospects for two of its...To view the full article, register now.
Already a subscriber? Click here to view full article